ImageneBio, Inc. Files 8-K
Ticker: IMA · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1835579
| Field | Detail |
|---|---|
| Company | Imagenebio, INC. (IMA) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financial-statements
TL;DR
ImageneBio filed an 8-K on Nov 19, 2025, with financial updates.
AI Summary
ImageneBio, Inc. filed an 8-K on November 19, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Ikena Oncology, Inc. until December 8, 2020, is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This 8-K filing indicates routine corporate reporting, including financial statements and exhibits, which provides transparency to investors about the company's current status.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for corporate reporting and does not appear to contain significant new risks or material events.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's fiscal year for financial reporting.)
Key Players & Entities
- ImageneBio, Inc. (company) — Registrant
- Ikena Oncology, Inc. (company) — Former Company Name
- November 19, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
- 001-40287 (identifier) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report under Regulation FD and to include financial statements and exhibits.
When was ImageneBio, Inc. formerly known as?
ImageneBio, Inc. was formerly known as Ikena Oncology, Inc.
On what date was the name change from Ikena Oncology, Inc. to ImageneBio, Inc. effective?
The date of the name change was December 8, 2020.
Where are ImageneBio, Inc.'s principal executive offices located?
ImageneBio, Inc.'s principal executive offices are located at 12526 High Bluff Drive, Suite 345, San Diego, California, 92130.
What is the SEC file number for ImageneBio, Inc.?
The SEC file number for ImageneBio, Inc. is 001-40287.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-11-19 07:50:18
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IMA The Nasdaq Capital Ma
Filing Documents
- d834017d8k.htm (8-K) — 25KB
- d834017dex991.htm (EX-99.1) — 33KB
- g834017ex99_1p10g1.jpg (GRAPHIC) — 333KB
- g834017ex99_1p11g1.jpg (GRAPHIC) — 249KB
- g834017ex99_1p12g1.jpg (GRAPHIC) — 251KB
- g834017ex99_1p13g1.jpg (GRAPHIC) — 243KB
- g834017ex99_1p14g1.jpg (GRAPHIC) — 329KB
- g834017ex99_1p15g1.jpg (GRAPHIC) — 317KB
- g834017ex99_1p16g1.jpg (GRAPHIC) — 346KB
- g834017ex99_1p17g1.jpg (GRAPHIC) — 245KB
- g834017ex99_1p18g1.jpg (GRAPHIC) — 310KB
- g834017ex99_1p19g1.jpg (GRAPHIC) — 342KB
- g834017ex99_1p1g1.jpg (GRAPHIC) — 167KB
- g834017ex99_1p20g1.jpg (GRAPHIC) — 300KB
- g834017ex99_1p21g1.jpg (GRAPHIC) — 358KB
- g834017ex99_1p22g1.jpg (GRAPHIC) — 318KB
- g834017ex99_1p23g1.jpg (GRAPHIC) — 432KB
- g834017ex99_1p24g1.jpg (GRAPHIC) — 336KB
- g834017ex99_1p25g1.jpg (GRAPHIC) — 145KB
- g834017ex99_1p2g1.jpg (GRAPHIC) — 592KB
- g834017ex99_1p3g1.jpg (GRAPHIC) — 313KB
- g834017ex99_1p4g1.jpg (GRAPHIC) — 448KB
- g834017ex99_1p5g1.jpg (GRAPHIC) — 372KB
- g834017ex99_1p6g1.jpg (GRAPHIC) — 448KB
- g834017ex99_1p7g1.jpg (GRAPHIC) — 212KB
- g834017ex99_1p8g1.jpg (GRAPHIC) — 258KB
- g834017ex99_1p9g1.jpg (GRAPHIC) — 349KB
- 0001193125-25-286984.txt ( ) — 11226KB
- ima-20251119.xsd (EX-101.SCH) — 3KB
- ima-20251119_lab.xml (EX-101.LAB) — 18KB
- ima-20251119_pre.xml (EX-101.PRE) — 11KB
- d834017d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Corporate Presentation of the Company Dated November 19, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMAGENEBIO, INC. Date: November 19, 2025 By: /s/ Kristin Yarema Kristin Yarema, Ph.D. Chief Executive Officer